Somewhat Positive Media Coverage Somewhat Unlikely to Impact MannKind (MNKD) Share Price

Media stories about MannKind (NASDAQ:MNKD) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9371757351571 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities analysts have weighed in on MNKD shares. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a report on Tuesday, October 24th. BidaskClub downgraded shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Maxim Group reissued a “hold” rating on shares of MannKind in a report on Wednesday, November 1st. Zacks Investment Research downgraded shares of MannKind from a “hold” rating to a “sell” rating in a report on Wednesday, December 13th. Finally, ValuEngine raised shares of MannKind from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $1.89.

MannKind (MNKD) opened at $2.57 on Wednesday. MannKind has a 1-year low of $0.67 and a 1-year high of $6.96. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. The company has a market cap of $299.55, a price-to-earnings ratio of -9.52 and a beta of 3.18.

MannKind (NASDAQ:MNKD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.11). MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The company had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.56 million. During the same period last year, the firm posted $1.30 EPS. MannKind’s quarterly revenue was down 98.7% compared to the same quarter last year. research analysts expect that MannKind will post -1.13 EPS for the current fiscal year.

In related news, VP Stuart A. Tross bought 39,840 shares of the stock in a transaction dated Thursday, December 21st. The shares were purchased at an average price of $2.52 per share, with a total value of $100,396.80. Following the completion of the acquisition, the vice president now owns 59,840 shares of the company’s stock, valued at $150,796.80. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.10% of the stock is currently owned by insiders.

WARNING: This story was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.com-unik.info/2018/02/07/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-mannkind-mnkd-share-price.html.

About MannKind

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit